建立一日法口服乙酰唑胺(ACZ)负荷脑血流显像技术并探讨其临床价值。对 30 名缺血性脑血管病患者在一日内行静息显像和口服乙酰唑胺负荷显像。观察负荷前后脑血管反应性和比较静息显像、负荷显像和CT 检查三者的阳性率。结果是大脑皮质对乙酰唑胺的反应可分为四种类型;CT、静息显像和负荷检查的阳性率分别为 23.3%、26.7%、86.7%。负荷显像阳性率高于单纯静息显像(p<0.05)和 CT 检查(p<0.01)。结论是一日法口服乙酰唑胺负荷显像省时并且经济,可提高缺血性脑血管疾病的诊断率,并反映血管储备能力,值得推广。 To establish a one-day oral acetazolamide (ACZ) load of cerebral blood flow imaging technology and explore its clinical value. Thirty patients with ischemic cerebrovascular disease underwent open imaging and oral acetazolamide load imaging in one day. Cerebral vascular reactivity was observed before and after the load and compared with resting imaging, load imaging and CT examination of the positive rate of the three. The result is that the cerebral cortex response to acetazolamide can be divided into four types; CT, resting imaging and load test positive rates were 23.3%, 26.7%, 86.7%. The positive rate of load imaging was higher than that of resting imaging (p <0.05) and CT (p <0.01). The conclusion is that one-day oral acetazolamide load imaging is time-saving and economical, which can improve the diagnosis rate of ischemic cerebrovascular diseases and reflect the reserve capacity of blood vessels, which is worth promoting.